Skip to content

Ibogaine research published in 2016

20 studies whose primary subject is ibogaine were published in 2016, up from 13 in 2015. Newest first. Back to the ibogaine overview

Studies

Quantification of Anti-Addictive Alkaloids Ibogaine and Voacangine in In Vivo- and In Vitro-Grown Plants of Two Mexican Tabernaemontana Species.

Chemistry & Biodiversity December 1, 2016 Felix Krengel, Josefina Herrera Santoyo, Teresa de Jesús Olivera Flores et al. 19 citations

Tabernaemontana alba and Tabernaemontana arborea are Apocynaceae species used in Mexican traditional medicine for which little phytochemical information exists. In this study, preliminary gas chromatography/mass spectrometry analyses of different organs obtained from wild plants of both species identified a total of 10 monoterpenoid indole alkaloids (MIAs) and one simple indole alkaloid, nine...

DOI: 10.1002/cbdv.201600146 (opens in new tab) Full text (opens in new tab) Ibogaine Tabernaemontana alba Tabernaemontana arborea Monoterpenoid indole alkaloid +8

Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.

Clinical Pharmacology in Drug Development November 1, 2016 Paul Glue, Gavin Cape, Donna Tunnicliff et al. 66 citations

Ibogaine is a psychoactive substance that may reduce opioid withdrawal symptoms. This was the first clinical trial of noribogaine, ibogaine's active metabolite, in patients established on methadone opioid substitution therapy (OST). In this randomized, double-blind, placebo-controlled single ascending-dose study, we evaluated the safety, tolerability, and pharmacokinetics of noribogaine in 27...

Pharmacological Chaperones of the Dopamine Transporter Rescue Dopamine Transporter Deficiency Syndrome Mutations in Heterologous Cells.

Journal of Biological Chemistry October 14, 2016 Pieter Beerepoot, Vincent M Lam, Ali Salahpour 59 citations

A number of pathological conditions have been linked to mutations in the dopamine transporter gene, including hereditary dopamine transporter deficiency syndrome (DTDS). DTDS is a rare condition that is caused by autosomal recessive loss-of-function mutations in the dopamine transporter (DAT), which often affects transporter trafficking and folding. We examined the possibility of using...

Death related to consumption of Rauvolfia sp. powder mislabeled as Tabernanthe iboga.

Forensic Science International September 1, 2016 Thomas Gicquel, Chloé Hugbart, Françoise Le Devehat et al. 20 citations

Powdered roots of iboga (Tabernanthe iboga) contain ibogaine, an alkaloid that has been used to treat addictions. We report the case of a 30-year-old woman who died after ingesting a powder labeled as Tabernanthe iboga she had bought online. Analysis of the powder revealed the absence of ibogaine but the presence of toxic alkaloids (ajmaline, yohimbine and reserpine) found in Rauvolfia sp....

Ibogaine for treating drug dependence. What is a safe dose?

Drug and Alcohol Dependence September 1, 2016 Leo J. Schep, Robin J Slaughter, S Galea et al. 30 citations

The indole alkaloid ibogaine, present in the root bark of the West African rain forest shrub Tabernanthe iboga, has been adopted in the West as a treatment for drug dependence. Treatment of patients requires large doses of the alkaloid to cause hallucinations, an alleged integral part of the patient's treatment regime. However, case reports and case series continue to describe evidences of...

DOI: 10.1016/j.drugalcdep.2016.07.005 (opens in new tab) Full text (opens in new tab) Drug dependence Qt prolongation Ibogaine treatment ibogaine Current ibogaine doses +6

Effects of low dose ibogaine on subjective mood state and psychological performance.

Journal of Ethnopharmacology August 2, 2016 Bridget Forsyth, Liana Machado, Tim Jowett et al. 35 citations

Root bark from Tabernanthe iboga has been used traditionally in West Africa as a psychoactive substance in religious rituals. In smaller doses it is reported anecdotally to have stimulant properties. To evaluate the influence of a single 20mg ibogaine dose on psychological variables reflecting subjective mood state and a range of cognitive functions. 21 healthy male volunteers received single...

DOI: 10.1016/j.jep.2016.05.022 (opens in new tab) Full text (opens in new tab) Noribogaine Ibogaine study: ibogaine Low-dose ibogaine Single 20mg dose +11

Functional Rescue of a Misfolded Drosophila melanogaster Dopamine Transporter Mutant Associated with a Sleepless Phenotype by Pharmacological Chaperones.

Journal of Biological Chemistry August 1, 2016 Ameya Kasture, Ali El-Kasaby, Daniel Szöllősi et al.

Folding-defective mutants of the human dopamine transporter (DAT) cause a syndrome of infantile dystonia/parkinsonism. Here, we provide a proof-of-principle that the folding deficit is amenable to correction in vivo by two means, the cognate DAT ligand noribogaine and the HSP70 inhibitor, pifithrin-μ. We examined the Drosophila melanogaster (d) mutant dDAT-G108Q, which leads to a sleepless...

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.

Journal of Psychopharmacology July 1, 2016 Deborah C. Mash, Barbara Ameer, Delphine Prou et al. 29 citations

This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administration of noribogaine. Oral noribogaine dose dependently decreased the global opiate withdrawal score by up to 88% of...

DOI: 10.1177/0269881116641331 (opens in new tab) Full text (opens in new tab) Cns drugs Blood–brain barrier Conditioned place preference Drug brain penetration +5

Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Translational Psychiatry May 31, 2016 Maarten Belgers, M Leenaars, Judith R. Homberg et al. 64 citations

Ibogaine is a naturally occurring substance which has been increasingly used in the lay-scene to reduce craving and relapse in patients with substance use disorders (SUDs). Although human clinical trials on the safety and efficacy of ibogaine are lacking, animal studies do support the efficacy of ibogaine. In this systematic review and meta-analysis (MA), we summarise these animal findings,...

DOI: 10.1038/tp.2016.71 (opens in new tab) Full text (opens in new tab) Ibogaine Addiction treatment Drug self-administration reduction Curbing addictive behaviors +11

Bioinspired Collective Syntheses of Iboga-Type Indole Alkaloids.

Organic Letters May 20, 2016 Gaoyuan Zhao, Xingang Xie, Haiyu Sun et al. 64 citations

We present the application of a bioinspired collective synthesis strategy in the total syntheses of seven iboga-type indole alkaloids: (±)-tabertinggine, (±)-ibogamine, (±)-ibogaine, (±)-ibogaine hydroxyindolenine, (±)-3-oxoibogaine hydroxyindolenine, (±)-iboluteine, and (±)-ervaoffines D. In particular, tabertinggine and its congeners serve as iboga precursors for the subsequent biomimetic...

DOI: 10.1021/acs.orglett.6b00989 (opens in new tab) Full text (opens in new tab) Ibogaine Bioinspired synthesis Biomimetic synthesis Collective synthesis +10

Control of serotonin transporter phosphorylation by conformational state.

Proceedings of the National Academy of Sciences May 17, 2016 Yuan-Wei Zhang, Benjamin E Turk, Gary Rudnick 53 citations

Serotonin transporter (SERT) is responsible for reuptake and recycling of 5-hydroxytryptamine (5-HT; serotonin) after its exocytotic release during neurotransmission. Mutations in human SERT are associated with psychiatric disorders and autism. Some of these mutations affect the regulation of SERT activity by cGMP-dependent phosphorylation. Here we provide direct evidence that this...

DOI: 10.1073/pnas.1603282113 (opens in new tab) Full text (opens in new tab) Ibogaine Phosphorylation Serotonin transporter Conformational regulation

Ibogaine-associated cardiac arrest and death: case report and review of the literature.

Therapeutic Advances in Psychopharmacology April 1, 2016 Jessica A Meisner, Susan R Wilcox, Jeremy B Richards 19 citations

A naturally occurring hallucinogenic plant alkaloid, ibogaine has been used as an adjuvant for opiate withdrawal for the past 50 years. In the setting of an escalating nationwide opiate epidemic, use of substances such as ibogaine may also increase. Therefore, familiarity with the mechanisms and potential adverse effects of ibogaine is important for clinicians. We present the case report of a...

DOI: 10.1177/2045125315626073 (opens in new tab) Full text (opens in new tab) Medication effects Ibogaine adverse effects Ibogaine complications Ibogaine side effects +11

Treatment of heroin dependence with ibogaine

European Psychiatry March 1, 2016 Arnt Schellekens, Toon Van Oosteren, Thomas Knuijver et al. 1 citation

Background The use of the hallucinogen ibogaine as an anti-addiction agent has been described in several case reports, dating back to the eighties. The anti-addiction properties of ibogaine have been confirmed in a large body of animal work. Ibogaine has been shown to be effective in reducing withdrawal severity and substance use for a variety of substances, including cocaine and opiates....

DOI: 10.1016/j.eurpsy.2016.01.799 (opens in new tab) Opiate Pharmacology Hallucinogen Heroin +1

Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound.

ACS Chemical Biology January 15, 2016 Madalee M Gassaway, Teresa L Jacques, Andrew C Kruegel et al. 23 citations

Modulation of growth factor signaling pathways in the brain represents a new experimental approach to treating neuropsychiatric disorders such as depression, anxiety, and addiction. Neurotrophins and growth factors exert synaptic, neuronal, and circuit level effects on a wide temporal range, which suggests a possibility of rapid and lasting therapeutic effects. Consequently, identification of...

DOI: 10.1021/acschembio.5b00678 (opens in new tab) Full text (opens in new tab) Addiction Neuroprotection Brain protection Neurological protection +22

hERG Blockade by Iboga Alkaloids.

Cardiovascular toxicology 2016 Kenneth Alper, Rong Bai, Nian Liu et al. 35 citations

The iboga alkaloids are a class of naturally occurring and synthetic compounds, some of which modify drug self-administration and withdrawal in humans and preclinical models. Ibogaine, the prototypic iboga alkaloid that is utilized clinically to treat addictions, has been associated with QT prolongation, torsades de pointes and fatalities. hERG blockade as IKr was measured using the whole-cell...

DOI: 10.1007/s12012-015-9311-5 (opens in new tab) Full text (opens in new tab) Noribogaine 18-methoxycoronaridine 18-mc Toxicology Iboga alkaloids research +1

How toxic is ibogaine?

Clinical Toxicology 2016 Ruud P. W. Litjens, Tibor M Brunt 74 citations

Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga. It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity. A search of the literature available on PubMed was done,...

Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys.

Journal of pharmacological and toxicological methods 2016 Simon Authier, Michael V Accardi, Dominique Paquette et al. 10 citations

Continuous video-electroencephalographic (EEG) monitoring remains the gold standard for seizure liability assessments in preclinical drug safety assessments. EEG monitored by telemetry was used to assess the behavioral and EEG effects of noribogaine hydrochloride (noribogaine) in cynomolgus monkeys. Noribogaine is an iboga alkaloid being studied for the treatment of opioid dependence. Six...

DOI: 10.1016/j.vascn.2016.04.012 (opens in new tab) Full text (opens in new tab) Cynomolgus monkey Electroencephalography Pentylenetetrazol Noribogaine seizure safety +1

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Journal of Psychoactive Drugs 2016 Laurie Cloutier-Gill, Evan Wood, Trevor Millar et al. 22 citations

Opioid use disorders (OUD) translate into major health, social, and economic consequences. Opioid agonist medications, which generally require long-term administration, are the mainstay pharmacological treatment of OUD. However, a large proportion of individuals with OUD either refuse or fail to respond to these therapies. Ibogaine, a naturally occurring substance found in the Tabernanthe iboga...

DOI: 10.1080/02791072.2016.1180467 (opens in new tab) Full text (opens in new tab) Methadone maintance therapy Opioid agonist treatment Opioid use disorders Ibogaine treatment +7